Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Down 21.3% in October

Atyr PHARMA INC (NASDAQ:ATYR) was the recipient of a significant decline in short interest in October. As of October 15th, there was short interest totalling 1,070,000 shares, a decline of 21.3% from the September 30th total of 1,360,000 shares. Currently, 1.5% of the shares of the stock are sold short. Based on an average daily volume of 684,000 shares, the days-to-cover ratio is currently 1.6 days.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ATYR. HC Wainwright reiterated a “buy” rating and issued a $35.00 target price on shares of Atyr PHARMA in a research report on Tuesday. Wells Fargo & Company began coverage on shares of Atyr PHARMA in a research note on Friday, October 4th. They issued an “overweight” rating and a $17.00 target price on the stock. Jefferies Financial Group began coverage on Atyr PHARMA in a report on Thursday, September 5th. They set a “buy” rating and a $9.00 target price on the stock. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $16.00 price target on shares of Atyr PHARMA in a report on Wednesday, August 14th.

Atyr PHARMA Trading Up 7.2 %

Atyr PHARMA stock traded up $0.24 during midday trading on Tuesday, hitting $3.56. 503,636 shares of the stock were exchanged, compared to its average volume of 557,523. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.63 and a quick ratio of 7.63. The stock’s 50-day moving average price is $2.11. Atyr PHARMA has a fifty-two week low of $1.08 and a fifty-two week high of $3.68. The firm has a market cap of $245.68 million, a PE ratio of -4.04 and a beta of 1.21.

Atyr PHARMA (NASDAQ:ATYR) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.01. Equities analysts anticipate that Atyr PHARMA will post -0.91 EPS for the current fiscal year.

About Atyr PHARMA

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.